Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes
Condition
Diverse malignancies either associated with or thought to be associated with activated
tyrosine kinase enzymes including hypereosinophilic syndrome systemic mastocytosis chronic
myelomonocytic leukaemia, dermatofibrosarcoma protuberans and other diseases.
Not included:
Patients with chronic myeloid leukemia, some other types of leukemias (abl-mutated) some
types of gastrointestinal stromal tumours (c-KIT-positive), some systemic mastocytosis (if
c-KIT D816V mutation), brain, prostate, breast or lung cancers.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
To assess the efficacy and the safety of imatinib mesylate therapy
2 years
Yes
Novartis Pharmaceuticals
Study Director
Novartis Pharmeceuticals
Australia: Department of Health and Ageing Therapeutic Goods Administration
CSTI571BAU12
NCT00171912
September 2004
January 2012
Name | Location |
---|